Oscar Health’s first quarter results prompted a positive market reaction as management delivered substantial improvements in profitability, even as revenue came in below consensus. CEO Mark Bertolini attributed the performance to disciplined expense management, robust membership growth, and the growing impact of artificial intelligence (AI) across operations. Notably, Oscar’s medical loss ratio improved sharply, and management highlighted the effectiveness of new technology-driven transparency tools and member support features.

Is now the time to buy OSCR? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Oscar Health’s Q1 Earnings Call

• Jessica Tassan (Barclays): Asked about the behavior and utilization patterns of members who dropped coverage after Q1. CFO Scott Blackley explained that most were non-paying members with minimal utilization, and churn proceeded as expected, with no unusual cost impact.
• John Ransom (Raymond James): Inquired why the SG&A ratio remained low despite suppressed revenue from higher risk adjustment. Blackley clarified that cost leverage from membership growth and operating efficiency drove the improvement, but SG&A may trend higher later in the year as expenses normalize.
• Andrew Mok (Barclays): Questioned risk adjustment transfer levels and the impact of the increased bronze plan mix. Blackley noted that higher risk adjustment is expected to moderate as claims normalize, and that current member risk profiles are tracking as anticipated.
• Olivia Miles (Baird): Sought details on the financial impact and scaling of the Lucie Health Marketplace. CEO Mark Bertolini described Lucie as a high-margin, capital-light model with modest financial effect this year, but significant long-term growth potential.
• Raj Kumar (Stephens): Asked about market-level enrollment trends and the effect of competitor exits. Blackley and Bertolini said effectuation rates and member transitions were in line or modestly favorable, and Oscar’s proactive broker support and product design captured membership left by exiting competitors.

Catalysts in Upcoming Quarters

Going forward, key watchpoints include (1) the pace at which Oscar scales the Lucie Health Marketplace and ICHRA X platforms, (2) the evolution of risk adjustment accruals and their impact on margins as member utilization normalizes, and (3) continued evidence that AI-driven initiatives are reducing administrative costs. Progress on these fronts will be critical to supporting Oscar’s strategy of profitable growth in the individual health insurance market.

Oscar Health currently trades at $23.35, up from $17.94 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.